From a drug-development perspective, METRNL illustrates the limitations of receptor-centric paradigms
So, let's say your protocol calls for a 100mcg dose of each peptide
In infants, pyridoxine deficiency can cause irritability, abnormallyacute hearing, and seizures, which are unresponsive to anticonvulsants but respond to pyridoxine supplementation ( A study performed by Yang and Wang in 2009 showed in-vivo study that pyridoxine can inhibit glutamate release from cerebrocortical synaptosomes by suppressing voltage-dependent Ca2+ entry
[3] Di Paola R, Modafferi S, Siracusa R, Cordaro M, D'Amico R, Ontario ML, Interdonato L, Salinaro AT, Fusco R, Impellizzeri D
Similarly, although SDF-1 may ameliorate kidney injury and promote repair after nondiabetic ischemia [26], potentiation of the chemokine can contribute to a proliferative response that leads to glomerulosclerosis, podocyte loss, and albuminuria [27, 28], thus implicating SDF-1 in the pathogenesis of diabetic nephropathy